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To evaluate the diagnostic accuracy of a single CEA (carcinoembryonic antigen) blood test
in detecting colorectal cancer recurrence.
Background
Patients who have undergone curative resection for primary colorectal cancer are typically
followed up with scheduled CEA testing for 5 years. Decisions to investigate further (usually
by CT imaging) are based on single test results, reflecting international guidelines.
Methods
A secondary analysis was undertaken of data from the FACS trial (two arms included CEA
testing). The composite reference standard applied included CT-CAP imaging, clinical
assessment and colonoscopy. Accuracy in detecting recurrence was evaluated in terms of
sensitivity, specificity, likelihood ratios, predictive values, time-dependent area under the
ROC curves, and operational performance when used prospectively in clinical practice are
reported.
Results
Of 582 patients, 104 (17.9%) developed recurrence during the 5 year follow-up period.
Applying the recommended threshold of 5μg/L achieves at best 50.0% sensitivity (95% CI:
40.1–59.9%); in prospective use in clinical practice it would lead to 56 missed recurrences
(53.8%; 95% CI: 44.2–64.4%) and 89 false alarms (56.7% of 157 patients referred for inves-
tigation). Applying a lower threshold of 2.5μg/L would reduce the number of missed recur-
rences to 36.5% (95% CI: 26.5–46.5%) but would increase the false alarms to 84.2% (924/
1097 referred). Some patients are more prone to false alarms than others—at the 5μg/L
threshold, the 89 episodes of unnecessary investigation were clustered in 29 individuals.
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Conclusion
Our results demonstrated very low sensitivity for CEA, bringing to question whether it could
ever be used as an independent triage test. It is not feasible to improve the diagnostic perfor-
mance of a single test result by reducing the recommended action threshold because of the
workload and false alarms generated. Current national and international guidelines merit re-
evaluation and options to improve performance, such as making clinical decisions on the
basis of CEA trend, should be further assessed.
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide, with approximately
40,000 new cases diagnosed each year in the UK [1]. The survival rate for patients diagnosed
with CRC has improved notably over the last few decades due to advances in chemotherapy
and an increase in the use of hepatic resection surgery [2]. Nonetheless, many patients still go
on to experience recurrence and delays in detection may reduce the possibility and effective-
ness of surgical intervention [3]. Approximately 85% of recurrences occur within 30 months
of surgery, and nearly all occur within 5 years [4]. Consequently, most national and interna-
tional guidelines recommend that patients who have undergone curative resection for primary
colorectal cancer are typically followed up for 5 years with scheduled blood carcino-embryonic
antigen (CEA) testing; typically, further investigation with CT imaging is recommended if the
CEA test result is above 5μg/L [5, 6].
Earlier this year, our research group completed a Cochrane systematic review of 52
studies exploring the accuracy of a CEA testing in detecting CRC recurrence [7]. We found
that very few studies had analysed the accuracy of CEA in a way that represents how single
CEA tests would be interpreted in clinical practice (according to guideline recommenda-
tions). Many of the studies simply looked at the accuracy of the CEA value measured closest
to the time of diagnosis; in others it was unclear as to which CEA value(s) were actually
being evaluated. As CEA is actually used as a monitoring test and repeated throughout
follow-up, just considering the CEA value closest to diagnosis of recurrence is potentially
misleading—for example, it is likely to underestimate the number of false positive results
(i.e. results which trigger unnecessary CT and other investigations because the CEA is
raised when no recurrence is detectable). A recent audit of the results of CEA follow-up
highlighted the scale of this problem in clinical practice, with further imaging investigations
triggered by a CEA level above the recommended threshold failing to confirm recurrence
in 50% of cases [8].
Since the initiation of our review, the interim findings of the FACS (Follow-up After Colo-
rectal Surgery) trial have been published [9]. This trial is the largest and most up to date rando-
mised trial comparing different follow-up strategies for patients who have undergone curative
surgery for primary colorectal cancer. Here we present a secondary analysis reporting the diag-
nostic accuracy of CEA within this trial. We report analyses consistent with those identified in
existing studies (in order to facilitate inclusion in the next review update), but also an addi-
tional analysis which demonstrates how CEA would perform prospectively in clinical practice
if guideline recommendations are followed.
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Methods
Study design
The data originates from the FACS (Follow-up After Colorectal Surgery) trial, a 2x2 pragmatic
randomised factorial controlled trial comparing minimum post-surgery follow-up of CRC
patients with 3–6 monthly CEA tests and 6–12 monthly computerised tomography (CT) imag-
ing [9]. All participants were recruited between January 2003 and August 2009. We analysed
the two arms of the trial which required frequent CEA testing (CEA only arm: n = 300,
CEA&CT arm: n = 302). The data analysed is available in S1 Dataset.
Ethical approval for the trial was granted by the National Health Service (NHS) South-West
Research Ethics Committee. Participants provided their written consent to participate in this
study
Of the 602 individuals included in the analysis, 106 had a recurrence within the 5 year fol-
low-up period (17.3%). The relatively low recurrence rate in this study has implications on
the precision in which we can estimate sensitivity. Assuming a sensitivity of 60%, 70% or
80%, we can expect 95% confidence intervals of 50.6–69.4%, 61.2–78.8%, or 72.3–87.7%
respectively.
Follow-up schedule
The follow-up schedule in both arms included CEA measurements every 3 months for the first
2 years and then every 6 months for the following 3 years. A composite reference standard was
used which consisted of CT CAP, clinical assessment at outpatient appointment (OPA review)
and colonoscopy. Those randomised to the CEA&CT arm received more frequent CT CAP
(see Fig 1. for details of schedule).
Any CEA value 7μg/L or more above baseline during follow-up was repeated within two
weeks. If the repeat CEA test was again>7μg/L, the GP urgently referred the patient for off-
protocol investigations for recurrence determined by the local surgeon. If the repeat CEA test
was<7μg/L above baseline the patient continued in the study as per protocol.
As a pragmatic open trial, it was not possible to conceal the allocation group from partici-
pants or clinicians, and radiologists reporting off protocol scans triggered by a rise in CEA
were not blinded to the reason for scanning.
Fig 1. 5-year follow-up schedule.
doi:10.1371/journal.pone.0171810.g001
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Technical specifications
Blood collection kits were sent directly to patients, who then attended their own general prac-
tice for phlebotomy. Blood samples were sent to the Biochemistry laboratory at the John Rad-
cliffe Hospital laboratory, Oxford. All CEA samples were analysed using a Siemens Centaur
XP analyser. Repeat tests were requested by sending a letter and sample kit to the patient ask-
ing them to schedule an appointment at their GPs for the repeat test. Imaging studies were
reported by a consultant radiologist.
All CT imaging was conducted on the highest quality equipment available in the collaborat-
ing centres. MRI scanning was an acceptable alternative to CT if performed in a study centre.
Statistical analyses
Two alternative methods for evaluating the accuracy of CEA were identified in our Cochrane
review—a ‘final CEA value’ analysis and an ‘any rise’ analysis [10]. For the ‘final CEA value’
analysis, the accuracy of the CEA measurement taken closest to the time that recurrence for
predicting recurrence is reported. For patients that do not experience recurrence, the CEA
measurement taken at the end of follow-up is evaluated instead. Alternatively, as CEA is being
monitored and CEA measurements are interpreted prospectively, the ‘any rise’ analysis
involved looking across all CEA measurements available for any rise in CEA above a given
threshold. We replicate both of these analytic approaches here.
Receiver Operating Characteristic (ROC) curves are produced alongside 95% bootstrap
confidence intervals to explore how accuracy varies with threshold using the pROC package in
R [11]. The area under the curve is also presented. The 2 x 2 data underpinning these plots is
available on request for meta-analysis purposes. Given that censoring is present in the dataset
under analysis, we also produced time-dependent ROC curves [12] and report the associated
AUCs at years 1–5. Sensitivity and specificity, likelihood ratios, and predictive values (along
with their respective 95% confidence intervals) are summarised for the most commonly rec-
ommended and implemented threshold of 5μg/L.
An operational analysis of the likely impact of CEA testing if used prospectively in clinical
practice was also conducted, hypothetically applying different absolute thresholds (from 2.5 to
10 μg/L) to trigger further investigation on the basis of the result of each individual test done
during the follow-up period. In relation to the CEA test scheduled at each time point, two out-
comes are reported: 1) the proportion of recurrences that would have been missed and not
referred for further investigation because the CEA level was below the threshold; 2) the pro-
portion of patients with a CEA level above the threshold who were subject to a false alarm (i.e.
an unnecessary referral for further investigation of a patient who did not experience recur-
rence throughout the whole follow-up period). The data for the 7.5μg/L and 10μg/L threshold
are less robust than for 5μg/L and 2.5μg/L thresholds as they were above the action threshold
applied in the FACS trial and therefore influenced more by work-up bias; they are reported in
S2 and S3 Tables for completeness.
The R code for the analyses reported is available in S1 Code File.
Results
The patient recruitment process for FACS and the reasons for any exclusions can be found in
S1 Fig. Of the 582 patients undergoing CEA follow-up, 104 (17.9%; 95% CI: 15.0% to 21.2%)
developed a recurrence during the 5-year follow-up period. As expected, the primary cancer
was more advanced among those who went on to experience recurrence. Other than this,
there were no notable differences between those who experienced recurrence and those who
did not (see S1 Table).
CEA for detecting colorectal cancer recurrence
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Diagnostic accuracy
As described in the methods, we estimated accuracy in relation to: 1) any rise across all CEA
measurements done prior to diagnosis; 2) the final CEA measurement done before the diagno-
sis. Fig 2 depicts accuracy for these two analyses across all thresholds; the area under the ROC
curve (AUC) is slightly better when just the final CEA value taken is analysed compared to
looking across all measurements (final CEA value AUC = 0.80, 95% CI: 0.75–0.86); all CEA
measurements AUC = 0.74, 95% CI: 0.68–0.80).
Due to the censored nature of the CEA data, time-dependent ROC curves were also pro-
duced for years 1–5 (Fig 3). In both analyses, it is evident from the reported area under the
ROC curves that the accuracy of CEA is notably poorer for patients who recur in the first year
of follow-up compared to subsequent years.
Fig 2. ROC curves depicting the accuracy of the final CEA value (left) and any rise above threshold (right). The
sensitivities and specificities achieved at thresholds of 2.5, 5, 7.5 and 10μg/L are highlighted.
doi:10.1371/journal.pone.0171810.g002
Fig 3. Time-dependent ROC curves depicting the accuracy of the final CEA value (left) and any rise above
threshold (right).
doi:10.1371/journal.pone.0171810.g003
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Table 1 presents the sensitivity, specificity, likelihood ratios, and predictive values for both
analyses at the commonly recommended threshold of 5μg/L. Including only the final CEA test
results in a slightly lower estimate of sensitivity and negative likelihood ratio but a more
favourable estimate of all the other diagnostic performance parameters. However, both analy-
ses are retrospective and therefore provide a potentially misleading picture of how CEA per-
forms operationally when used prospectively in clinical practice.
Operational performance
Table 2 shows the estimated operational performance of CEA monitoring in clinical practice
when two different thresholds for initiating further investigation are applied prospectively: the
current standard threshold of 5μg/L and a potentially more sensitive threshold of 2.5μg/L.
Table 1. Comparison of the diagnostic performance in detecting recurrence of a rise in blood CEA level above a threshold of 5μg/L in relation to i)
all CEA measurements taken prior to diagnosis of recurrence and ii) the final CEA measurement taken prior to diagnosis of recurrence.
Final CEA measurement (95% CI) All CEA measurements (95% CI)
Sensitivity 49.0% (39.2–59.0%) 50.0% (40.1–59.9%)
Specificity 97.5% (95.5–98.6%) 93.3% (90.6–95.3%)
Positive predictive value 81.0% (68.7–89.4%) 61.9% (50.6–72.1%)
Negative predictive value 89.8% (86.8–92.2%) 89.6% (86.5–92.0%)
Positive likelihood ratio 19.5 (10.8–35.3) 7.5 (5.1–11.0)
Negative likelihood ratio 0.52 (0.43–0.63) 0.54 (0.44–0.65)
doi:10.1371/journal.pone.0171810.t001
Table 2. Estimated operational performance of CEA in clinical practice at currently recommended intervals if further investigation is triggered by
thresholds of 2.5 and 5 μg/L.
Time of test CEA tests Recurrences 5μg/L action threshold 2.5 μg/L action threshold
Missed cases False alarms Missed cases False alarms
Year Month n n n (%) n/N (%) n (%) n/N (%)
Year 1 3 563 15 9 3/15 7 63/88
6 542 17 10 6/16 10 68/92
9 530 7 3 2/9 2 68/87
12 519 12 7 8/15 3 66/86
All 2154 51 29 (56.9%) 19/55 (34.5%) 22 (43.1%) 265/353 (75.1%)
Year 2 15 500 7 3 2/8 1 62/76
18 493 7 4 9/12 2 67/80
21 482 1 0 6/7 0 64/70
24 477 11 7 8/12 5 65/78
All 1952 26 14 (53.8%) 25/39 (64.1%) 8 (30.8%) 258/304 (84.9%)
Year 3 30 455 6 4 7/10 4 67/76
36 444 7 1 9/16 0 68/80
All 899 13 5 (38.5%) 16/26 (61.5%) 4 (30.8%) 135/156 (86.5%)
Year 4 42 427 6 2 6/11 0 71/81
48 408 5 3 7/9 2 69/74
All 835 11 5 (45.5%) 13/20 (65.0%) 2 (18.2%) 140/155 (90.3%)
Year 5 54 395 2 2 12/12 2 65/66
60 374 1 1 4/5 0 61/63
All 769 3 3 (100%) 16/17 (94.1%) 2 (66.7%) 126/129 (97.7%)
All years 6609 104 56 (53.8%) 89/157 (56.7%) 38 (36.5%) 924/1097 (84.2%)
doi:10.1371/journal.pone.0171810.t002
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The number of recurrences diagnosed by the composite gold standard (and therefore
potentially identifiable by a rise in CEA) in each testing period falls from a mean of 12.8 in
year 1 (2.2% of patients at risk) to 1.5 in year 5 (0.31% of patients at risk), despite the reduction
in frequency of testing from 3 to 6 monthly after year 2. Overall, CEA correctly identifies the
need for further investigation in just under half the cases of recurrence applying a threshold of
5μg/L (46.2%, 95% CI: 36.6–55.8) and just under two-thirds with a threshold of 2.5μg/L
(63.5%, 95%CI: 54.2–72.8). There is no clear trend in the proportion of missed cases over time.
If the threshold is increased, the overall number of missed cases over the 5 year follow-up
period increases to 62.5% at 7.5μg/L and 75.0% at 10μg/L (S2 and S3 Tables).
Unnecessary investigations
Table 2 also shows the cost of reducing the threshold from 5 to 2.5μg/L in terms of investiga-
tive workload and false alarms. At 5μg/L, only 157 of 6609 (2.4%) of CEA tests trigger further
investigation compared to 1097 (16.6%) at 2.5μg/L. The number of false alarms increases from
about 1 in 2 (56.7%) at 5μg/L to 5 in 6 (84.2%) at 2.5μg/L. The proportion of false alarms also
increases over time with both thresholds—from 34.5 to 94.5% at 5μg/L and from 75.1 to 97.7%
at 2.5μg/L in years 1 and 5 respectively.
Some patients are more prone to false alarms than others. For example, the 89 unnecessary
investigations triggered at a threshold of 5μg/L were clustered in 29 individuals, 15 of whom
(51.7%) would have more than one false alarm, 8 more than 5 false alarms. At a threshold of
2.5μg/L, the 924 false alarms are clustered in 156 people, of whom 114 (73.0%) would have
more than one false alarm and 69 more than 5 false alarms. The estimated maximum number
of false alarms in one patient over a 5 year period are 10 at 5μg/L and 14 at 2.5μg/L. Full details
are given in S4 Table.
S2 and S3 Tables show that unnecessary investigations are a much smaller problem with the
higher thresholds of 7.5 and 10μg/L, with only 4 and 2 false alarms generated respectively, with
no patients suffering more than one false alarm.
Discussion
Main findings
CEA must not be used alone as a means of monitoring for colorectal cancer recurrence. What-
ever threshold is applied, a significant number of patients suffer recurrence without a rise in
CEA levels. At the ASCO recommended threshold of 5μg/L, about half the recurrences will be
missed. This underlines the importance of combining CEA with scheduled imaging, as recom-
mended in most national guidelines. In the comparative analysis of the FACS trial, when com-
bined with a single CT-CAP scan at 12–18 months, CEA follow-up performed as well in
detecting treatable recurrence as 6-monthly CT-CAP imaging [9].
Although the sensitivity of CEA testing can be increased by reducing the threshold to
2.5μg/L (approximately the threshold recommended as optimal by Tan et al [13]), the cost is
high. A 7-fold increase in imaging workload is not sustainable in many health economies
(such as the UK NHS) and the very high rate of false alarms (5 out of 6 referrals for further
investigation) is unlikely to be acceptable to patients. Importantly, some people will suffer
recurrent false alarms.
Consistency with existing evidence
The modest sensitivity of CEA at the recommended 5μg/L threshold is well documented—in
our Cochrane review, the pooled sensitivity based on 23 studies was higher than estimated by
CEA for detecting colorectal cancer recurrence
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our own data (71%, 95% CI: 64–76%) but nearly a third of cases would still be missed [10]. We
have criticised the meta-analysis methods used by Tan et al in their 2009 systematic review,
but for comparison they reported a sensitivity of 63% at a threshold of 5μg/L and 84% at a
threshold of 2.2μg/L [13]. Our reported specificity is also consistent with previous studies
although operational performance (i.e. imaging workload and false alarms) will depend on
testing interval and prevalence of recurrence in the population being followed-up.
Strengths and limitations
The main strengths of the FACS trial data in this context is that CEA testing was centrally
managed with high compliance with scheduled testing and all analyses being done in one labo-
ratory with consistent quality control. The main strength of this analysis compared to previous
diagnostic accuracy studies of CEA in detecting recurrence of which we are aware, is that we
modelled the operational performance of CEA when used prospectively in clinical practice,
rather than simply looking retrospectively at sensitivity and specificity in relation to a series of
tests.
The main limitation of the data is that we do not have a reference standard at all time
points. We do not know the precise time when a recurrence would have been detectable by
our gold standard. Our estimate of unnecessary referrals is likely to be an underestimate as it
only includes patients who did not experience recurrence throughout the whole follow-up
period. However, the length of follow-up and within-trial surveillance means that we are
unlikely to have missed cases of recurrence. Even if we had been able to apply the gold stan-
dard at every time-point, there may be a lead-time between detectability of recurrence by CEA
and by imaging.
The other important limitation is work-up bias. Patients in the FACS with a CEA>7μg/L
above their personal baseline were referred for further investigation. This relatively high
threshold means that the analyses of diagnostic accuracy at the thresholds of 2.5μg/L and
7.5μg/L are largely not subject to bias but the estimates of operational performance at 10μg/L
reported in the S2 and S3 Tables are less robust.
Finally, the analysis we report here (and most previous studies of which we are aware) assess
the diagnostic performance of CEA in detecting any recurrence. We did not have a sufficient
number of cases of recurrence to stratify the analysis by the treatability of recurrence.
Implications for clinical practice and research
CEA has three great advantages over other forms of follow-up: it is relatively inexpensive, can
be done in a community setting, and does not expose the patient to radiation. It can therefore
be done more frequently than other tests and has the potential to provide important lead-time
in detecting recurrence (about 3 months in the FACS trial). However, our data underlines that
it must not be used alone as a triage test because of its low sensitivity.
Sensitivity can clearly be increased by reducing the threshold but, as stated above, the
impact on workload and high false alarm rate make that a very unattractive solution. However,
it is probably time to stop making decisions to investigate further on the basis of a single test
result when a series of tests have been done. About 40 years ago Minton et al argued convinc-
ingly that the diagnostic accuracy of blood CEA testing in detecting colorectal cancer recur-
rence would be improved by taking account of trend over time [14] and others have since
provided strong supportive evidence [15, 16]. We have already shown on the basis of FACS
data that much better diagnostic performance, including better sensitivity, can be achieved by
basing the decision to investigate further on the regression co-efficient derived from a series of
tests [17].
CEA for detecting colorectal cancer recurrence
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The main implication of our data for further research is that traditional methods of assess-
ing and reporting the diagnostic accuracy of a single test provide an inadequate guide to the
clinical performance of a test which is actually used as a monitoring tool in practice. Research
into the accuracy of monitoring tests needs to be designed to assess performance at each indi-
vidual time point and to take account of the added information provided by sequential testing.
Further research into the value of CEA as a monitoring test needs to focus on the detection of
recurrence at an optimal stage for treatment.
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